Kinetics of Nirogacestat-Mediated Increases in B-cell Maturation Antigen on Plasma Cells Inform Therapeutic Combinations in Multiple Myeloma.
| Autor: | Shearer T; SpringWorks Therapeutics, Inc., Stamford, Connecticut., Comstock M; Fred Hutchinson Cancer Center, Translational Science and Therapeutics Division, Seattle, Washington., Williams RL Jr; SpringWorks Therapeutics, Inc., Stamford, Connecticut., Johnson MC; SpringWorks Therapeutics, Inc., Stamford, Connecticut., Cendrowicz E; ICON BioAnalytical Laboratories, Assen, the Netherlands., Leonowens C; Independent Consultant, Sanford, North Carolina., Smith M; SpringWorks Therapeutics, Inc., Stamford, Connecticut., Baughman TM; SpringWorks Therapeutics, Inc., Stamford, Connecticut., Breitbach CJ; SpringWorks Therapeutics, Inc., Stamford, Connecticut., Cheng S; SpringWorks Therapeutics, Inc., Stamford, Connecticut., Green DJ; Fred Hutchinson Cancer Center, Translational Science and Therapeutics Division, Seattle, Washington.; Division of Transplantation and Cellular Therapy, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cancer research communications [Cancer Res Commun] 2024 Dec 01; Vol. 4 (12), pp. 3114-3123. |
| DOI: | 10.1158/2767-9764.CRC-24-0075 |
| Abstrakt: | Significance: GSIs can enhance multiple myeloma therapies targeting BCMA by increasing mbBCMA on plasma cells. In response to the GSI nirogacestat, mbBCMA rapidly and robustly increased in vitro and in vivo. Elucidating nirogacestat's effects on BCMA kinetics will guide potential multiple myeloma dosing strategies. (©2024 The Authors; Published by the American Association for Cancer Research.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|